Name | Deslanoside |
Synonyms | sediranido cedilanidd Deslanoside DESLANOSIDUM deslanatoside descetyldigilanidec deacetyl-lanatoside desacetyllanatosidec DEACETYLLANATOSIDE C Card-20(22)-enolide, 3-[(O-β-D-glucopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3β,5β,12β)- |
CAS | 17598-65-1 |
EINECS | 241-568-1 |
InChI | InChI=1/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1 |
Molecular Formula | C47H74O19 |
Molar Mass | 943.08 |
Density | 1.1255 (rough estimate) |
Melting Point | 220-235°C |
Boling Point | 732.1°C (rough estimate) |
Specific Rotation(α) | D20 +12° (c = 1.084 in 75% alc) |
Solubility | Soluble in methanol, DMSO |
Appearance | Powder |
pKa | 12.89±0.70(Predicted) |
Storage Condition | 2-8°C |
Sensitive | Easily absorbing moisture |
Refractive Index | 1.6500 (estimate) |
In vitro study | Deslanoside (Desacetyllanatoside C) is a metabolite of Lanatoside C. Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity measured as an indicator of centrally mediated sympathetic nervous system activity. |
Risk Codes | R23/25 - Toxic by inhalation and if swallowed. R33 - Danger of cumulative effects |
Safety Description | S1 - Keep locked up. S22 - Do not breathe dust. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | 2811 |
HS Code | 2938900000 |
Reference Show more | 1. Ding Yanxia, Wang Xiaoqin, Zhang Ying. Determination of six major phenylethanol glycosides in Cistanche based on high performance liquid chromatography [J]. Shi Zhen, Chinese medicine, 2020,31(04):813-816. |
This product is glucopyranosyl-(1-4)-02, 6-dideoxy-B-D-nuclear-hexopyranosyl-(1-4)-02, 6-dideoxy-B-D-nuclear-hexopyranosyl-(1-4)-0-2, 6-dideoxy-B-D-nuclear-hexopyranosyl] OxO]-12,14-dihydroxy-steroidine-20 (22)-enolactone. According to the calculation of dry product, containing C47H74019 should be 96.0% ~ 102.0%.
take this product, precision weighing, add anhydrous pyridine to dissolve and quantitatively dilute to make a solution containing about 20mg per lml, and determine according to law (General rule 0621), the specific rotation should be 7 to 9°C.
take this product, add a small amount of methanol to dissolve, dilute with mobile phase to make a solution containing about 0.2mg per 1ml, as a test solution; Take 1ml with precision, set in a 100ml measuring flask, dilute to the scale with the mobile phase, and shake to serve as a control solution. Test according to high performance liquid chromatography (General 0512). Silica gel bonded with eighteen alkyl silane was used as filler; Water was used as mobile phase A; Acetonitrile-methanol (22:14) was used as mobile phase B; The detection wavelength was 220nm. The gradient elution is carried out according to the following table, and the separation degree of the peak of the flower and the adjacent impurity peaks should meet the requirements. Accurately take 20 u1 of the test solution and the control solution respectively, and inject the human Liquid Chromatograph. If there are impurity peaks in the chromatogram of the test solution, the single impurity peak area shall not be greater than 2.5 times (2.5%) of the main peak area of the control solution, and the sum of the impurity peak areas shall not be greater than 5 times (5.0%) of the main peak area of the control solution.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 1.0% (General rule 0831).
cardiotonic drugs.
light shielding, sealed storage.
This product is a sterilization solution made by adding 10% ethanol to the flower of acetic acid. The content of deacetylanosine (C47H74019) shall be between 90.0% and 110.0% of the labeled amount.
This product is a clear colorless liquid.
measured by high performance liquid chromatography (General 0512).
Chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica as filler; Acetonitrile-methanol-water (232:148:620) as mobile phase, the detection wavelength was 220nm. The number of theoretical plates is calculated according to the peak of deacetylanthocyanin, and the degree of separation between the peak of deacetylanthocyanin and the adjacent impurity peaks shall meet the requirements.
Determination of this product as a test solution, the precise amount of 20ul, injection of human liquid chromatography, record chromatogram f, take the other acetyl flower glycosides control, precision weighing, plus a small amount of methanol ultrasonic dissolution, A solution containing about 0.2mg per 1 ml was prepared by quantitative dilution with mobile phase and determined by the same method. According to the external standard method to calculate the peak area, that is.
Same as deacetyl flower glycoside.
2ml : 0.4mg
light shielding, closed storage.
introduction | deacetyl linarin is white crystalline powder. No odor, bitter taste; It has wettiness. This product is slightly soluble in methanol, slightly soluble in ethanol, and almost insoluble in water or chloroform. |
indications | for acute and chronic heart failure, atrial fibrillation and paroxysmal supraventricular tachycardia. Since this product is not as stable as deacetylanthocyanin in solution, the latter is mostly used for injection. This product is only sometimes used for oral administration, but because the absorption from the gastrointestinal tract is not as good as digitoxin, and the absorption is irregular, oral administration is also less used. |
biological activity | Deslanoside (Desacetyllanatoside C) is a fast-acting cardiac glycoside used to study congestive heart failure and supraventricular arrhythmia caused by reentry mechanism, and control ventricular rate when studying chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. |
use | heart disease medication. |